This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Keryx: Readers React to Perifosine Prediction

The data we had from the Detsky paper looked at stock prices four months before the announcement of phase III trial results, so we emulated that timeline in our analysis. It's true that Keryx's market value was greater than $300 million at one time, but again, that doesn't drastically improve perifosine's odds based on our observations.

@dondet comments, "Ok, even if perifosine Ph3 will fail, that won't nec'rly cancel an EOY pps runup - w/median analysts' PT @ $9.00."

Does everyone understand Twitter speak? Translated: Even if perifosine's phase III study is predicted to fail, that won't necessarily cancel an end-of-year run-up in Keryx's stock price, especially with analysts' median price target set at $9 per share.

True enough. I'm not making any predictions about Keryx's stock price between now and when the company announces results from the perifosine study in the first quarter. Keryx is the sort of biotech stock with a near-term catalyst that traders and speculative investors love.

Bob Temple writes, "What you wrote this morning was very disappointing, not because of your thesis (it's true that most drug programs fail), but because it went against everything you have advocated to biotech investors for a long time -- reading beyond press releases, going through SEC filings, and ultimately doing your own homework. Deciding the probability of success based on the due diligence of Big Pharma doesn't sound consistent with that methodology. Also, having a partnership/buyer doesn't guarantee success either."

I appreciate your thoughts but the "Feuerstein-Ratain rule" is just another way thinking about cancer drug stocks. I don't mean to say that it should replace fundamental research. In fact, our thesis piggybacks on the fundamental research that we believe is done by the market i.e. investors and other, larger pharmaceutical companies. To coin a cutesy phrase, you can think of this thesis as a "meta-fundamental" analysis of cancer drugs.

I also agree that having a partner doesn't guarantee success. Aventis (SNY) was once partnered with Genta (GNTA). Takeda hooked up with Cell Genesys. Schering-Plough (MRK) partnered with Novacea. All resulted in cancer drug blow ups.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
7 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,143.37 +11.40 0.07%
S&P 500 2,001.21 +2.23 0.11%
NASDAQ 4,559.1310 +6.3720 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs